1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
MUROMACHI CHEMICALS INC.

MUROMACHI CHEMICALS INC.

TTSE:4885
923.00
JPY
-3.00
(-0.32%)
4.11BMarket Cap
Jan 08Next Earn
MUROMACHI CHEMICALS INC.
TSE:4885
(Tokyo Stock Exchange)

Recent

price

923.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
2026
TTM
JPY
0.08
2,636.1
1,784.6
1,541.38
1,667.72
1,609.09
1,665.98
1,951.71
- -
Revenue per Share
6.33
17.16
65.24
123.79
67.94
83.42
60.42
40.58
- -
Basic EPS, GAAP
-4.35
3.51
155.9
96.2
54.85
100.68
-30.11
142.64
- -
Free Cash Flow per Basic Share
0.26
0.6
0.54
14.88
18.72
18.82
21.85
34.84
- -
Dividend per Share
50.73
73.22
363.93
450.37
487.31
571.26
612.4
640.13
640.13
Book Value per Share
43.59
68.36
360.47
439.65
469.54
555.02
599.12
629.69
629.69
Tangible Book Value per Share
5
2
3
4
4
4
4
4
4
Basic Weighted Avg Shares
- -
5,282
4,943
5,681
6,291
6,369
6,653
7,841
- -
Sales/Revenue/Turnover
33,251.27
5.7
7.47
7.7
5.87
6.62
6.5
9.48
- -
Operating Margin (%)
271
218
124
101
122
136
162
191
- -
Depreciation Expense
29
34
181
456
256
330
241
163
- -
Net Income, GAAP
- -
- -
9.47
- -
26.96
29.53
31.07
50.31
- -
Effective Tax Rate (%)
8,190.65
0.65
3.66
8.03
4.07
5.18
3.63
2.08
- -
Profit Margin (%)
297
290
1,380
1,269
1,526
1,888
2,153
2,475
2,475
Working Capital
1,940
1,192
988
785
873
1,103
1,243
1,203
1,203
LT Debt
182
252
1,334
1,681
1,915
2,271
2,452
2,577
2,577
Total Equity
- -
- -
9.64
- -
7.8
8.14
7.47
8.18
- -
Return on Invested Capital (%)
- -
- -
5.98
- -
7.86
9.54
6.69
4.23
- -
Return on Capital (%)
- -
15.82
22.79
30.27
14.25
15.77
10.22
6.48
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Nov'25
Nov'26
May'26
ST Debt
414
650
901
LT Borrowings
1,442
1,766
1,202
LT Finance Leases
- -
- -
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
2,896
2,959
4,114

Working Capital

JPY

•

in mil. unless spec.
Nov'25
Nov'26
May'26
Total Current Assets
3,901
4,775
4,932
Cash, Cash Equivalents & STI
1,329
1,876
1,947
Accounts Receivable, Net
814
1,009
1,120
Inventories
1,344
1,369
906
Total Current Liabilities
1,621
1,936
2,457
Payables & Accruals
- -
- -
- -
ST Debt
414
650
901
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
14.32%
5.09%
Free Cash Flow
- -
-134.72%
-576.51%
Net Income, GAAP
- -
15.62%
-32.43%
Sales/Revenue/Turnover
- -
9.85%
17.86%
Total Cash Common Dividend
- -
741.02%
60.46%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,517
1,396
1,543
1,914
6,369
2025
- -
- -
- -
- -
6,653
2026
- -
- -
- -
- -
7,841

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5.76
17.85
24.52
35.15
83.42
2025
- -
- -
- -
- -
60.42
2026
- -
- -
- -
- -
40.58

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
18.82
2025
- -
- -
- -
- -
21.85
2026
- -
- -
- -
- -
34.84
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Muromachi Chemicals Inc. (4885.T) manufactures, distributes, and sells pharmaceuticals, health foods, chemicals, and functional materials primarily in Japan. The company operates through four main segments offering active pharmaceutical ingredients including calcium polystyrene sulfonate, potassium warfarin, and histamine dihydrochloride; intermediate synthesis products and commissioned synthesis services for radioactive and stable isotope-tagged compounds; ion-exchange resins, separation membranes, water-treatment equipment, and chemicals; health foods such as traditional tablets, jellies, and non-alcoholic beverages; and functional materials like adhesives, antistatic products, and custom-made pastes for electronics and other industries. Founded in January 1917 and formally established in July 1947, Muromachi Chemicals is headquartered in Omuta, Fukuoka, with additional facilities including a Tokyo branch, Osaka office, Tsukuba Plant, and Pharmaceutical R&D Center in Chiba. The company targets pharmaceutical manufacturers, healthcare providers, industrial clients in water treatment and electronics, and consumers, with import/export activities involving partners in China, India, and Europe. In recent developments, Muromachi Chemicals strengthened its development and sales systems for new areas including per- and polyfluoroalkyl substances (PFAS) treatment, contributing to revenue growth in the fiscal year ending May 2025; announced a "10 billion declaration" targeting 10 billion yen in revenue by May 2031 from a base of 6.4 billion yen; and expanded focus on pharmaceuticals amid trends of Japanese firms repatriating API production while deepening ties with overseas suppliers in high-risk regions.